18F‑Pentixafor PET imaging for blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study uses 18F‑NOTA‑Pentixafor, a PET tracer that binds the CXCR4 receptor, to image patients with suspected or confirmed hematologic malignancies. Participants will receive the tracer and undergo PET imaging about one hour after injection, with image quality and lesion detection compared to standard imaging and available pathology. The study aims to determine whether 18F‑Pentixafor provides better spatial resolution or broader applicability than 18F‑FDG across different blood cancers. Data will include diagnostic performance, staging information, and response evaluation in treated patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age of 18-80 years old, both sexes, with behavioral capacity;
2. patients with suspected or confirmed hematological malignancies;
3. 18F-FDG PET or other imaging examinations should be performed according to the treatment plan;
4. For suspected patients, biopsy or needle biopsy is expected to obtain pathological results;
5. Can provide informed consent, can understand and comply with the requirements of the study.

Exclusion Criteria:

1. pregnant and lactating women;
2. patients with fear or radiophobia, or with mental disorder or primary affective disorder;
3. received ionizing radiation outside the scope of this study for clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv;
4. received investigational drugs or devices of uncertain efficacy or safety within 1 month;
5. Any condition that the chairpersons of the study consider that any link related to the study may cause harm or have potential harm.

Where it's running

• The First Affiliated Hospital of Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Peipei Wang, MD
• Email: wpp199411@163.com
• Phone: 86 18511395988

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lower Dose Cyclophosphamide After Haploidentical Stem Cell Transplant

  This trial tests whether giving half the usual amount of cyclophosphamide after haploidentical stem cell transplantation can still prevent GVHD in adults with blood cancers.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07719946

• Chlorophyllin to reduce mouth sores before allogeneic stem cell transplant

  This phase II study tests whether taking chlorophyllin by mouth can lower the chances and severity of mouth ulcers in patients aged 12–65 undergoing radiation-based conditioning before a first allogeneic stem cell transplant.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra · NCT07709195

• First-in-human test of DS3790a for hematological malignancies

  This first-in-human trial will test DS3790a alone and with other drugs to see if it's safe, how it behaves in the body, and whether it helps adults with hematological malignancies.

  Recruiting at 8 sites Phase 1/2 Daiichi Sankyo · New York, New York and 7 other locations · NCT07220616

• Improving GVHD prevention after donor stem cell transplant

  This study will test whether a lower dose versus the standard dose of post-transplant cyclophosphamide, given with sirolimus and MMF, improves quality of life for people aged 60 and older having a reduced-intensity allogeneic stem cell transplant.

  Recruiting Phase 2 University of Nebraska · Omaha, Nebraska · NCT06799195

• Long-term follow-up for patients treated with Galapagos CAR T-cell therapies

  This study is checking how well Galapagos CAR T-cell therapies work and their safety for patients over 15 years after treatment.

  Recruiting at 11 sites Phase 3 Lakefront Biotherapeutics NV · Boston, Massachusetts and 10 other locations · NCT06652633

• Longitudinal study of CAR-T cell therapy in patients with blood cancers

  This study looks at how well CAR-T cell therapy works for Chinese patients with blood cancers by gathering information from those who have already received this treatment.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06607289

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.